share_log

Redhill Biopharma | SC 13G: Statement of acquisition of beneficial ownership by individuals-CVI Investments, Inc.(5.9%),Heights Capital Management, Inc.(5.9%)

Redhill Biopharma | SC 13G：超過5%持股股東披露文件-CVI Investments, Inc.(5.9%),Heights Capital Management, Inc.(5.9%)

SEC announcement ·  02/01 10:26
Moomoo AI 已提取核心訊息
On January 25, 2024, CVI Investments, Inc., with Heights Capital Management, Inc. as its investment manager, filed a Schedule 13G with the Securities and Exchange Commission, disclosing a 5.9% ownership stake in RedHill Biopharma Ltd., amounting to 700,000,000 shares. This stake is represented by 1,750,000 American Depositary Shares, following the company's recent share offering completion. The filing, made under Rule 13d-1(c), indicates that the shares were not acquired for the purpose of changing or influencing the control of RedHill Biopharma. Both CVI Investments and Heights Capital Management are organized under the laws of the Cayman Islands and Delaware, respectively. The filing was certified by Brian Sopinsky, Secretary of both entities, on February 1, 2024.
On January 25, 2024, CVI Investments, Inc., with Heights Capital Management, Inc. as its investment manager, filed a Schedule 13G with the Securities and Exchange Commission, disclosing a 5.9% ownership stake in RedHill Biopharma Ltd., amounting to 700,000,000 shares. This stake is represented by 1,750,000 American Depositary Shares, following the company's recent share offering completion. The filing, made under Rule 13d-1(c), indicates that the shares were not acquired for the purpose of changing or influencing the control of RedHill Biopharma. Both CVI Investments and Heights Capital Management are organized under the laws of the Cayman Islands and Delaware, respectively. The filing was certified by Brian Sopinsky, Secretary of both entities, on February 1, 2024.
2024年1月25日，以Heights Capital Management, Inc.爲投資管理公司的CVI Investments, Inc.向美國證券交易委員會提交了附表13G，披露了紅山生物製藥有限公司5.9％的所有權，總額爲7億股。該公司最近完成股票發行後，該股份由1,750,000股美國存托股票代表。該文件是根據第13d-1（c）條提交的，表明收購這些股份不是爲了改變或影響RedHill Biopharma的控制權。CVI Investments和Heights Capital Management分別根據開曼群島和特拉華州的法律組建。該文件於2024年2月1日由兩個實體的秘書布萊恩·索平斯基認證。
2024年1月25日，以Heights Capital Management, Inc.爲投資管理公司的CVI Investments, Inc.向美國證券交易委員會提交了附表13G，披露了紅山生物製藥有限公司5.9％的所有權，總額爲7億股。該公司最近完成股票發行後，該股份由1,750,000股美國存托股票代表。該文件是根據第13d-1（c）條提交的，表明收購這些股份不是爲了改變或影響RedHill Biopharma的控制權。CVI Investments和Heights Capital Management分別根據開曼群島和特拉華州的法律組建。該文件於2024年2月1日由兩個實體的秘書布萊恩·索平斯基認證。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息